期刊文献+

细针穿刺细胞学结合免疫组织化学诊断转移性恶性黑色素瘤1例

下载PDF
导出
摘要 恶性黑色素瘤(mallgnant melanoma,MM)是一种来源于鳞状上皮基底层处黑色素细胞的恶性肿瘤,其侵袭性高,预后较差[1]。其发病率仅占皮肤恶性肿瘤的5%左右,但却占死亡构成比例的75%[1];且近年来其发病率和病死率在全球范围内均有升高的趋势[2]。由于肿瘤早期体积小,病变部位隐匿,常因远处转移病灶而被发现。MM皮损及瘤细胞形态多样,其确诊及鉴别诊断依赖临床表现和常规免疫组织化学方法。本文通过回顾分析细针穿刺(fine needle aspiration cytology,FNAc)检查的1例转移性MM,探讨FNAC涂片中细胞形态与人黑色素瘤抗体-45(HMB-45)和黑色素-A(Melan-A)标志物在诊断转移性MM中的价值。
作者 刘杰 罗波
出处 《重庆医学》 CAS 北大核心 2015年第20期2878-2879,共2页 Chongqing medicine
  • 相关文献

参考文献9

  • 1Parkin DM, Bray F, Ferlay J, et al. Global Cancer Stati- tisitics, 2002 [J]. CA Cancer J Clin, 2005,55 (2) : 74-108.
  • 2Jemal A, Seigel R,Ward E, et al. Cancer Statistics, 2006 [J]. Cancer J Clin,2006,56(2) :106-130.
  • 3Balch CM, Buzaid AC, Soong SJ, et al. Final version ofthe American Joint Committee on Cancer staging system for cutaneous melanoma[J]. J Clin Oncol, 2001,19 (16) : 3635-3648.
  • 4Robert C,Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma [J]. N Engl J Med,2011,364(26) ..2517-2526.
  • 5Ribas A, Kim KB, Schuchter LM, et al. BRIM-2 : an open- label,multicenter phase II study of vemurafenib in previ- ously treated patients with BRAF V600E mutation-posi- tive metastatic melanoma[J]. J Clin Oncol, 2011,29 (Sup- pl) :8509.
  • 6Ascierto PA, Berking C, Agarwala SS, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unreseetable or metastatic cutaneous melanoma har- boring BRAFV600 or NRAS mutations[J]. J Clin Oncol, 2012,30(Suppl 15) :8511.
  • 7余少鸿,汤荣春,Per H Basse.联合应用NK细胞及CTL对黑色素瘤B16细胞的影响[J].重庆医学,2012,41(9):878-880. 被引量:4
  • 8叶明福,张哉根,王亚丽,汤金梁.恶性黑色素瘤组织学变异型与鉴别诊断[J].临床与实验病理学杂志,2004,20(5):588-591. 被引量:39
  • 9黄春鑫,苗英.无色素性恶性黑色素瘤23例临床病理分析[J].临床与实验病理学杂志,2008,24(2):243-244. 被引量:12

二级参考文献30

  • 1黄春鑫,黄君健,李捷艳.淋巴结转移性多形性腺样无色素性恶性黑色素瘤一例[J].中华病理学杂志,2004,33(3):263-263. 被引量:4
  • 2叶明福,张哉根,王亚丽,汤金梁.恶性黑色素瘤组织学变异型与鉴别诊断[J].临床与实验病理学杂志,2004,20(5):588-591. 被引量:39
  • 3王丽霞,米哲涛,殷卫东,王全红,王晋芬.黏膜无色素性恶性黑色素瘤的免疫组化及临床研究[J].肿瘤研究与临床,2006,18(7):453-455. 被引量:8
  • 4Goding S,Yang Q,Mi Z,et al.Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells[J].Cancer Gene Ther,2007,14(5):441-450.
  • 5Bullock TN,Mullins DW,Colella TA,et al.Manipulation of avidity to improve effectiveness of adoptively trans-ferred CD8(+)T cells for melanoma immunotherapy in human MHC class I-transgenic mice[J].J Immunol,2001,167(10):5824-5831.
  • 6Aptsiauri N,Cabrera T,Mendez R,et al.Role of altered expression of HLA class I molecules in cancer progression[J].Adv Exp Med Biol,2007,601:123-131.
  • 7Méndez R,Ruiz-Cabello F,Rodríguez T,et al.Identifica-tion of different tumor escape mechanisms in several me-tastases from a melanoma patient undergoing immuno-therapy[J].Cancer Immunol Immunother,2007,56(1):88-94.
  • 8Kjaergaard J,Hokland M,Nannmark U,et al.Infiltration patterns of short-and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy[J].Scand J Immunol,1998,47(6):532-540.
  • 9Basse P,Goldfarb RH.Localization of immune effector cells to tumor metastases[J].Immunol Ser,1994,61:149-158.
  • 10Basse PH,Goldfarb RH,Herberman RB,et al.Accumula-tion of adoptively transferred A-NK cells in murine me-tastases:kinetics and role of interleukin-2[J].In Vivo,1994,8(1):17-24.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部